Newbury Pharmaceuticals Secures Generic Approval for Prukalopride

Newbury Pharmaceuticals AB received generic approval for prucalopride, allowing it to move toward commercializing the prescription drug in its target markets. The approval supports the company’s strategy to expand its specialty-treatment portfolio in the Nordic region. The announcement disclosed no financial terms or launch timeline.